Who owns Arcutis Biotherapeutics, Inc. (ARQT)? Elite investor 13F holders
4 tracked elite investors reported holding Arcutis Biotherapeutics, Inc as of 2026-06-30, including Rubric Capital, D.E. Shaw, Renaissance Technologies LLC, Gotham Asset Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
4 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Rubric Capital | ARCUTIS BIOTHERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 216880749.00 USD | 8271577.000000 | Shares | hold | Original filing |
| D.E. Shaw | ARCUTIS BIOTHERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 103558748.00 USD | 3949609.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | ARCUTIS BIOTHERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 1531222.00 USD | 58399.000000 | Shares | reduce | Original filing |
| Gotham Asset Management | ARCUTIS BIOTHERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 499019.00 USD | 19032.000000 | Shares | buy | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.